Strategies for Optimizing Adherence in Patients with Schizophrenia

Recovery in Schizophrenia
1 ANCC Contact Hours
Launch Date:
January 14, 2014
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Advanced Practice Registered Nurses, Psychiatric Registered Nurses, Registered Nurses

Relevant Terms:

Adherence, Long-Acting Injectable, Motivational Interviewing, Schizophrenia, Self-Determination Theory


Associate Professor
Specialty Coordinator, Psychiatric-Mental Health Nursing

Yale University School of Nursing
New Haven, CT

Dr. Mary D. Moller is an Associate Professor at the Yale University School of Nursing where she is the Specialty Coordinator for Psychiatric-Mental Health Nursing. She is an Advanced Practice Registered Nurse dually certified as a clinical specialist in adult psychiatric-mental health nursing and a psychiatric rehabilitation practitioner. Dr. Moller received her bachelor's degree in nursing from Mount Marty College in Yankton, South Dakota; her master's degree in psychiatric-mental health nursing from the University of Nebraska Medical Center College of Nursing in Omaha; and her doctor of nursing practice degree from Case Western Reserve University in Cleveland, Ohio. She received the Case Western Dean's Legacy Award for her research entitled The Lived Experience of the Patient with Schizophrenia in the Postpsychotic Adjustment Phase of Recovery from Psychosis.

From 1992 to 2008 she was the Clinical Director of The Suncrest Wellness Center, an outpatient psychiatric clinic in Spokane, Washington, that was featured with Patty Duke on "Good Morning America." In addition to her administrative duties, she carried an ongoing caseload of over 250 patients where she was responsible for primary mental health care including assessment, diagnosis, prescribing and monitoring psychotropic medications, individual, family, and group psychotherapy, and ongoing program outcomes research. She is also President of NurSeminars, Inc., an international consulting and lecture firm related to psychiatric nursing. From 2008 to 2009 she was Adjunct Associate Professor at Kansas University School of Nursing in Kansas City, Kansas, where she developed their first Web-based psychopharmacology course for psychiatric nurse practitioner students. Dr. Moller has served as consultant to both the Israeli and Singapore Ministry of Health Divisions of Psychiatric Nursing.

For the past 20 years she has been an active member of the American Psychiatric Nurses Association. In 2008 she was elected president-elect and assumed the presidency in October, 2009. Dr. Moller's research interests include schizophrenia, PTSD, and improving patient care and outcomes through psychiatric wellness. She has published and lectured extensively on these topics.

Joyce M. Shea, DNSc, APRN, PMHCNS-BC

Joyce M. Shea, DNSc, APRN, PMHCNS-BC
Associate Professor and Elizabeth DeCamp McInerney Professor of Health Sciences
Fairfield University School of Nursing
Fairfield, CT

Dr. Joyce M. Shea is an Associate Professor and the Elizabeth DeCamp McInerney Professor of Health Sciences at Fairfield University in Connecticut. She received her bachelor of science in nursing (BSN) from Fairfield University, and a master of science in nursing (MSN) and a doctorate in nursing science (DNSc) from Yale University School of Nursing in West Haven, Connecticut. She is an Advanced Practice Registered Nurse (APRN), with board certification as an Adult Psychiatric-Mental Health Clinical Nurse Specialist and more than 30 years' experience working in multiple modalities and diverse settings. In addition, she has completed train-the-trainer courses through both the End-of-Life Nursing Education Consortium and the Geriatric Nursing Education Consortium.  In the summer of 2008, she was one of 12 individuals chosen nationally for the Hartford Institute's Summer Geriatric Nursing Research Scholar Program at New York University.

Dr. Shea's clinical and research areas of interest have focused on individuals with severe and prolonged mental illness, especially those with schizophrenia. An expert in qualitative research, she has focused her studies on issues related to identity, self-recovery, and community living for those with severe mental illness. Her dissertation was a grounded theory study of the process by which individuals with schizophrenia recover their sense of a functional self. She has completed a pilot study of the needs of elderly individuals with schizophrenia, and is currently undertaking a funded study to explore the impact of incarceration on those with schizophrenia. Other areas of research interest involve curricular integration of topics such as palliative care, gerontology best practices, simulation pedagogy, and spirituality. She has published and lectured extensively on these topics.

Peter J. Weiden, MD

Peter J. Weiden, MD
Professor of Psychiatry
University of Illinois Medical Center
Chicago, IL

Dr. Peter J. Weiden is Professor of Psychiatry at the University of Illinois Medical Center in Chicago. Known for his work on patient and family education addressing the treatment of psychosis, much of Dr. Weiden's career has focused on improving clinical outcomes for patients with schizophrenia. His research has focused on bridging psychopharmacology and public health issues in the treatment of schizophrenia, and he has a particular interest in the use of cognitive behavioral therapy (CBT)–type interventions for individuals with psychotic disorders.

A frequent contributor to the medical literature, Dr. Weiden has authored or coauthored more than 150 journal articles as well as a number of books and practice guidelines. He has published extensively on the problem of nonadherence with antipsychotic medications.

Dr. Weiden has received several awards from advocacy groups and was named an Exemplary Psychiatrist on three separate occasions by the National Alliance on Mental Illness (NAMI). Dr. Weiden's book, breakthroughs in Antipsychotic Medications: A Guide for Patients, Families, and Clinicians (WW Norton & Co.), received the Ken Johnson Memorial Book Award in 2000 as one of the most outstanding books in mental health. For his research on relapse prevention, he received NAMI's Judith Silver Young Scientist Award in 1996. He has been listed in the "Best Doctors in New York" issue of New York magazine.

Active in many professional associations, Dr. Weiden is a member of the American Psychiatric Association, the International CBT for Psychosis Working Group, and the Academy of Cognitive Therapy. He also serves on NAMI's Scientific Advisory Board.

Dr. Weiden earned his bachelor's degree in chemistry from Swarthmore College in Pennsylvania and his medical degree from the State University of New York at Stony Brook. He completed his psychiatric residency at the Payne Whitney Clinic–New York Hospital and a psychiatric epidemiology fellowship at the Mailman School of Public Health of Columbia University in New York City.
1. Integrate evidence-based interventions for improved schizophrenia treatment adherence and compliance into daily practice
2. Discuss efficacy, safety and PK data for long-acting injectable antipsychotics (LAI) for schizophrenia
3. Select eligible patients for LAI intervention, and begin the dialog regarding LAI use
4. Provide appropriate care and counsel for patients and their families

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CNE activity:

  • Mary D. Moller, DNP, ARNP, APRN, PMHCNS-BC, CPRP, FAAN, has no affiliations with commercial interests to disclose.
  • Joyce M. Shea, DNSc, APRN, PMHCNS-BC, has no affiliations with commercial interests to disclose.
  • Peter J. Weiden, MD, has affiliations with Delpor, Johnson & Johnson (Janssen), Lundbeck, Otsuka USA, Merck, Novartis, Sunovion, Genentech/Roche (Consultant); Johnson & Johnson (Janssen), Merck, Novartis, Sunovion (Speakers' Bureau); Genentech/Roche, Johnson & Johnson (Janssen), NIMH, Novartis, Sunovion, Neurocrine (Grant Support); and Delpor (Stockholder).
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Cynthia M. Kunzer, CMP, has no affiliations with commercial interests to disclose.
  • The patient in this activity has no affiliations with commercial interests to disclose.

Postgraduate Institute for Medicine
  • Jan Hixon, RN, BSN, MA, has no affiliations with commercial interests to disclose.
  • Trace Hutchison, PharmD, has no affiliations with commercial interests to disclose.
  • Samantha Mattiucci, PharmD, has no affiliations with commercial interests to disclose.
  • Jan Schultz, RN, MSN, CCMEP, has no affiliations with commercial interests to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

This educational activity for 1.0 contact hours is provided by Postgraduate Institute for Medicine.

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity has been designed to meet the educational needs of registered nurses involved in the care of patients with schizophrenia.

Estimated time to complete:  60 minutes
Medium: Internet

There is no fee for this educational activity.

This activity is jointly sponsored by RMEI, LLC and Postgraduate Institute for Medicine. RMEI gratefully acknowledges an educational grant from Otsuka America Pharmaceutical, Inc. in support of this CNE activity.

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 ANCC Category 1 Credit(s)™. A statement of credit will be available to print from your user history page.
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Nurses who successfully complete the post-test and evaluation will receive CNE credit. You must score with a 70% or higher on the post-test to receive credit for this activity.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above